The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
Open accessAbstract
PURPOSE: Extraprostatic disease will be manifest in a third of men after radical prostatectomy. We present the long-term followup of a randomized clinical trial of radiotherapy to reduce the risk of subsequent metastatic disease and death. MATERIALS AND METHODS: A total of 431 men with pT3N0M0 prostate cancer were randomized to 60 to 64 Gy adjuvant radiotherapy or observation. The primary study end point was metastasis-free survival. RESULTS: Of 425 eligible men 211 were randomized to observation and 214 to adjuvant radiation. Of those men under observation 70 ultimately received radiotherapy. Metastasis-free survival was significantly greater with radiotherapy (93 of 214 events on the radiotherapy arm vs 114 of 211 events on observation; HR 0.71; 95% CI 0.54, 0.94; p = 0.016). Survival improved significantly with adjuvant radiation (88 deaths of 214 on the radiotherapy arm vs 110 deaths of 211 on observation; HR 0.72; 95% CI 0.55, 0.96; p = 0.023). CONCLUSIONS: Adjuvant radiotherapy after radical prostatectomy for a man with pT3N0M0 prostate cancer significantly reduces the risk of metastasis and increases survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Häggman, M., Andersson, S.-O., Bratell, S., Spångberg, A., Busch, C., Nordling, S., Garmo, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043739 · Cited by 1,111
Cited by
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Azad, A. A., Volik, S. V., Wyatt, A. W., Haegert, A., Le Bihan, S., Bell, R. H., Anderson, S. A., McConeghy, B., Shukin, R., Bazov, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2666 · Cited by 478
Positive Surgical Margins After Radical Prostatectomy: A Systematic Review and Contemporary Update
Yossepowitch, O., Briganti, A., Eastham, J. A., Epstein, J., Graefen, M., Montironi, R., & Touijer, K. (2014) · European Urology · doi:10.1016/j.eururo.2013.07.039 · Cited by 423
Vale, C. L., Fisher, D., Kneebone, A., Parker, C., Pearse, M., Richaud, P., Sargos, P., Sydes, M. R., Brawley, C., Brihoum, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31952-8 · Cited by 404
Carrie, C., Hasbini, A., de Laroche, G., Richaud, P., Guerif, S., Latorzeff, I., Supiot, S., Bosset, M., Lagrange, J.-L., Beckendorf, V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00111-x · Cited by 365
Metadata
- Authors
- Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., Canby-Hagino, E., & Crawford, E. D.
- Venue
- Journal of Urology
- Published
- 2009-03
- Volume
- 181
- Issue
- 3
- Pages
- 956-962
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2156306108
- Cited by
- 1,227
- References
- 2
- FWCI
- 83.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial. https://app.cochat.ai/papers/10.1016/j.juro.2008.11.032
- The paper
- Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., Canby-Hagino, E., & Crawford, E. D. (2009). Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial. Journal of Urology. https://doi.org/10.1016/j.juro.2008.11.032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
